School of Medical Sciences, University of Auckland, Auckland, New Zealand.
Ther Adv Med Oncol. 2010 Mar;2(2):125-48. doi: 10.1177/1758834009360519.
Over the last 10 years there has been an explosion of information about the molecular biology of cancer. A challenge in oncology is to translate this information into advances in patient care. While there are well-formed routes for translating new molecular information into drug therapy, the routes for translating new information into sensitive and specific diagnostic, prognostic and predictive tests are still being developed. Similarly, the science of using tumor molecular profiles to select clinical trial participants or to optimize therapy for individual patients is still in its infancy. This review will summarize the current technologies for predicting treatment response and prognosis in cancer medicine, and outline what the future may hold. It will also highlight the potential importance of methods that can integrate molecular, histopathological and clinical information into a synergistic understanding of tumor progression. While these possibilities are without doubt exciting, significant challenges remain if we are to implement them with a strong evidence base in a widely available and cost-effective manner.
在过去的 10 年中，有关癌症分子生物学的信息呈爆炸式增长。肿瘤学面临的挑战是将这些信息转化为患者护理的进步。虽然将新的分子信息转化为药物治疗的途径已经很完善，但将新信息转化为敏感和特异性诊断、预后和预测测试的途径仍在开发中。同样，利用肿瘤分子谱选择临床试验参与者或为个体患者优化治疗的科学仍处于起步阶段。这篇综述将总结目前用于预测癌症治疗反应和预后的技术，并概述未来可能的发展方向。它还将强调能够将分子、组织病理学和临床信息整合到对肿瘤进展的协同理解中的方法的潜在重要性。虽然这些可能性无疑令人兴奋，但如果我们要以强有力的证据基础广泛、经济有效地实施这些方法，仍然存在重大挑战。
